101 Hartwell Avenue
172 articles with T2 Biosystems
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, and CARB-X, a global non-profit partnership dedicated to accelerating early development antibacterial R&D to address the rising global threat of drug-resistant bacteria, announced today that the T2Resistance™ Panel is the first diagnostic to graduate from CARB-X’s portfolio.
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it entered into exclusive distribution agreements with five new distribution partners in the first half of 2019.
T2 Biosystems Introduces New Clinical Data and Updates Regarding Expanding Capabilities of its Rapid Diagnostic Technology at ASM Microbe 2019
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, will share multiple updates regarding the clinical utility of its expanding portfolio of groundbreaking rapid diagnostics and technology during ASM Microbe 2019 in San Francisco, CA from June 19 to 24.
Publication in Annals of Internal Medicine® Reveals T2Bacteria® Panel as the First Direct-from-Blood, Non-Culture Test that Rapidly Diagnoses Bacterial Bloodstream Infections
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that results from a pivotal trial were published online in the Annals of Internal Medicine® journal.
T2 Biosystems and Clinicians to Share Clinical Data in Integrated Symposium and Poster Presentations at the European Congress of Clinical Microbiology & Infectious Diseases
Data will highlight how direct-from-whole blood innovations—the T2Bacteria, T2Candida and T2Resistance panels—positively impact patients with bloodstream infections
T2 Biosystems Announces Customer Presentations at October ConferencesIDWeek and World Antimicrobial Resistance Congress to feature presentations on T2Bacteria and T2Candida Panels
T2 Biosystems, Inc. today announced upcoming scientific presentations that will be made by users of T2Direct Diagnostics™ at leading conferences in October.
FDA’s Approval of T2 Biosystems T2Bacteria Panel Underlines Importance of Sepsis Diagnosis and Tr...
7/10/2018On May 29, the FDA cleared T2 Biosystems’ T2Bacteria Panel for diagnosis of sepsis. In that sepsis is the third-leading cause of death in the U.S., this emphasizes the importance of work in this area.
The study also demonstrates the ability of the T2Candida Panel to identify clinically important infections missed by blood culture, while dramatically shortening the time to treat an infection with targeted therapy.
T2 Biosystems Announces Preliminary Fourth Quarter 2017 Financial Results and Provides Update on T2Bacteria Panel
The company closed 7 contracts with new customers in the fourth quarter including 3 new contracts for the T2Bacteria Research Use Only Panel in the United States.
These data highlight the potential clinical value that may be achieved using the T2Bacteria Panel compared to results from blood culture.
Reported third quarter total revenue of $1.1 million, in line with guidance. Product revenue of $739,000, was a $159,000 or 27.4% increase from the third quarter of 2016.
Here are four players that have the right combination of elements to post an earnings beat this quarter.
T2 Biosystems Announces 2017 Third Quarter Financial and Operational Results Release and Conference Call Date
T2 Biosystems will release its 2017 third quarter financial and operational results after the market closes on Thursday, November 2, 2017.
T2 Biosystems Release: Clinicians Discuss Positive Impact Of T2MR Platform On Sepsis Care At IDWeek 2017
T2 Biosystems Release: Study Published In Journal Of Antimicrobial Stewardship Shows Patients Diagnosed With T2Candida Panel Treated More Than Eight Times Faster
T2 Biosystems And Cidara Announce Partnership For Commercial Placement Of T2Dx Instruments To Support CD101 Drug Trials